Biomarker-Driven Oncology Trial Design and Subgroup Characterization: Challenges and Potential Solutions

Area of Science:

• Oncology
• Clinical Trial Design
• Biomarker Development

Background:

• Biomarkers are crucial for selecting patient populations likely to benefit from cancer therapies, enhancing clinical trial efficiency.
• Many oncology drugs approved by the US Food and Drug Administration (FDA) were initially tested in broad patient groups but later restricted to biomarker-defined subgroups.

Purpose of the Study:

• To analyze FDA-approved oncology therapeutics tested in "all-comers" populations but approved for biomarker-defined subgroups.
• To identify critical factors for regulatory benefit-risk assessments comparing biomarker-defined subgroups to all-comers approvals.
• To propose a decision tree for optimizing clinical trial design using patient enrichment and stratification strategies.

Main Methods:

• Review of pivotal trials for oncology therapeutics with "all-comers" designs that resulted in biomarker-defined subgroup approvals.
• Analysis of key considerations for regulatory benefit-risk assessments: biological/clinical rationale, biomarker prevalence, safety, trial design, and subgroup efficacy.
• Development of a decision tree for clinical trial design, incorporating marker type, prevalence, and assay logistics.
• Recommendation for prespecifying clinically meaningful improvement in biomarker-negative subgroups and using Bayesian methods for evidence integration.

Main Results:

• Favorable benefit-risk assessments were often established in biomarker-positive subgroups, even when trials included all-comers.
• Key factors influencing regulatory decisions include biological rationale, biomarker prevalence, safety data, and efficacy within subgroups.
• A decision tree is proposed to guide the choice between patient enrichment and stratification based on various factors.

Conclusions:

• Optimizing biomarker-driven drug development in oncology requires innovative clinical trial designs, robust statistical methodologies, and careful regulatory considerations.
• Strategic use of biomarkers can enhance the efficiency and success rate of oncology drug development.
• The analysis provides a framework for regulatory benefit-risk assessments and clinical trial design in the era of precision oncology.